At the annual Singapore Week of Innovation and Technology (SWITCH) 2023, Lion TCR, a clinical-stage mRNA-based T cell immunotherapy company, is thrilled to announce a significant milestone of clinching the T-Up Excellence Awards. This award, in recognition of remarkable contributions to the growth and innovation within Lion TCR and the broader Singapore biotech sector, have been also presented to Dr. Wai Lu-En, Lion TCR's Senior Director of Research and Development, and Dr. Sarene Koh, Director
27 June 2023, Lion TCR, a clinical-stage T-cell immunotherapy company, is thrilled to announce the successful completion of its USD 40 million Series B2 financing round. Guangzhou Industrial Investment and Capital Operation Holding Group Ltd. led the financing with participation from Guangzhou Guoju Investment and CSPC NARD Capital Fund. The funds raised will be used primarily to support Lion TCR's clinical trials on hepatitis B virus (HBV)-specific TCR T cell therapy, while also facilitating th
/PRNewswire/ Lion TCR Pte Ltd today announced that it has received Fast Track Designation from United States Food and Drug Administration (U.S. FDA) for.